AUTHORS
Sikander Ailawadhi, MD, Maria Gavriatopoulou, MD2, Jennifer L Peterson, MD3, Ioannis Ntanasis-Stathopoulos, MD4, Ariel F. Grajales-Cruz, MD5, Aimaz Afrough, MD6, Yair Levy, MD7, Judith Trotman, FRACP, FRCPA, MBChB8, Kimberley Doucette, MD9, Jorge J Castillo, MD10, Francisco Hernandez-Ilizaliturri, MD11, Ajay K Nooka, MD, MPH12, Shirley D'Sa, MD13, Ralph Vincent Boccia, MD14, Harsh Parmar, MD15, Carlos Fernandez de Larrea, MD, PhD16, Guldane Cengiz Seval, MD, PhD17, Sheeba Koshy Thomas, M.D.18, Kate Oliver, BS19, Jarrod Longcor20, Larry D Anderson Jr, MD, PhD21
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
3 Mayo Clinic, Jacksonville, Florida, United States
4 Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
5 Moffitt Cancer Center, Tampa, Florida, United States
6 UT Southwestern Medical Center, Dallas, Texas, United States
7 Texas Oncology, Dallas, Texas, United States
8 Concorde Repatriation General Hospital, Sydney, Australia
9 MedStar Georgetown University Hospital, Washington, District of Columbia, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
13 University College London Hospital, London, United Kingdom
14 The Center for Cancer and Blood Disorders, North Bethesda, Maryland, United States
15 John Theurer Cancer Center-Hackensack University Medical Center, Hackensack, New Jersey, United States
16 Hospital Clinico de Barcelona, Barcelona, Spain
17 Ankara University Faculty of Medicine Cebeci Hospital, Ankara, Turkey
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 Cellectar Biosciences, Florham Park, New Jersey, United States
20 Cellectar Biosciences, Florham Park, New Jersey, United States
21 UT Southwestern Medical Center, Dallas, Texas, United States
ABSTRACT
Background: Waldenström Macroglobulinemia (WM) is a B-cell malignancy characterized by bone marrow infiltration with clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM). Despite available treatments, such as Bruton Tyrosine Kinase inhibitors (BTKis), WM remains incurable. Treatment options for relapsed/refractory (R/R) pts are limited and often continuous, underscoring the need for new agents with novel mechanisms of action and pt-centered, fixed duration therapy. Iopofosine I 131 is a novel radiopharmaceutical compound composed of a lipid raft-targeting phospholipid ether covalently bound to 131I, a beta emitting radioisotope. Results are reported here of the CLOVER-WaM study [NCT02952508] in R/R WM pts with a minimum of 12 months of follow-up.
Aims: The primary efficacy endpoint was major response rate (MRR; partial response or better, as determined by the modified IWWM-VI). Secondary and exploratory endpoints included overall response rate (ORR), duration of response (DOR), and clinical benefit rate (CBR; stable disease or better). Efficacy endpoints were assessed in the modified intent-to-treat (mITT) population: all pts who received ≥60 mCi total administered dose of iopofosine I 131. Safety was evaluated using CTCAE v4.03 in pts who received ≥1 dose of iopofosine. Data cut off for this analysis was Dec 24, 2025.
Methods: Eligible WM pts received ≥2 prior therapies, preferably having relapsed or had a suboptimal response to BTKi and had measurable disease for assessment of response by the modified IWWM-VI.
Treatment consisted of 2 cycles of iopofosine I 131 administered at 15 mCi/m2 on days 1 and 15 of each 57-day cycle. Dose reduction to 10 mCi/m2 was allowed in the 2nd cycle in pts with incomplete hematologic recovery or if the expected total dose exceeded 132 mCi. Supportive care with growth factors and transfusions was permitted per treating physician discretion.
Results: As previously reported (Ailawadhi S, et al. 2024), 65 pts were dosed and 55 are included in the mITT population. All pts provided informed consent. Median age of pts was 70 years (range 50-88) and pts had a median of 4 prior lines of therapy (range 2-15). If exposed, pts were refractory to prior treatment as follows: BTKi 84.6% (33/39), anti-CD20 antibody 72% (36/50), chemotherapy 60% (27/45), and 64.7% (22/34) to both a BTKi and anti-CD20 antibody. MYD88 mutation was noted in 70.9% (39/55) of pts.
The MRR was 34/55 (61.8%), ORR was 46/55 (83.6%) and CBR was 54/55 (98.2%), median DOR was 17.8 months (range 2 to 41). Grade ≥ 3, related treatment emergent adverse events (TEAE) occurring in > 10% of pts included anemia (36%), leukopenia (27%), lymphopenia (15%), neutropenia (60%), and thrombocytopenia (80%).
Conclusion: In this heavily pretreated WM population, iopofosine I 131 demonstrated clinically meaningful anti-tumor activity, with a high ORR, substantial MRR, and a median DOR approaching 18 months. Responses were observed in a population characterized by advanced age, multiple prior lines of therapy, and a high proportion of BTKi-, anti-CD20-, and chemotherapy-refractory disease and multi-drug class refractory, underscoring the potential relevance of this novel mechanism of action in a setting of substantial unmet need. The safety profile was generally consistent with the known toxicity pattern of a cytotoxic radiotherapeutic, with hematologic AEs representing the principal treatment-related toxicities and warranting ongoing monitoring and supportive care.
DISCLOSURES
Sikander Ailawadhi, MD: BMS - Research Funding; Xencor - Research Funding; Cellectar - Research Funding; Janssen - Research Funding; Ascentage Pharma Group Inc. - Research Funding; Amgen - Research Funding; Pharmacyclics - Research Funding; AbbVie - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Cellectar - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)